Yudong Wang
Sar, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 10 publications
Risk factors related to low-level viraemia in chronic hepatitis B patients receiving entecavir treatment.
Journal: Frontiers in cellular and infection microbiology
Published: April 07, 2024
Achieving WHO target of HCV control in Hong Kong: challenges and strategies.
Journal: Global health & medicine
Published: June 18, 2021
Letter to the Editor: Obesity, diabetes, non-alcoholic fatty liver disease and metabolic dysfunction associated fatty liver disease are proinflammatory hypercoagulable states associated with severe disease and thrombosis in Covid-19.
Journal: Metabolism: clinical and experimental
Published: November 10, 2020
Effect of COVID-19 on patients with compensated chronic liver diseases.
Journal: Hepatology international
Published: May 19, 2020
Management of COVID-19 in patients after liver transplantation: Beijing working party for liver transplantation.
Journal: Hepatology international
Published: April 07, 2020
Non-alcoholic fatty liver diseases in patients with COVID-19: A retrospective study.
Journal: Journal of hepatology
Published: March 27, 2020
Efficacy and safety of 3-week response-guided triple direct-acting antiviral therapy for chronic hepatitis C infection: a phase 2, open-label, proof-of-concept study.
Journal: The lancet. Gastroenterology & hepatology
Published: December 06, 2016
Hepatitis B reactivation in hepatitis B and C coinfected patients treated with antiviral agents: A systematic review and meta-analysis.
Journal: Hepatology (Baltimore, Md.)
Published: September 28, 2016
Hepatitis due to Reactivation of Hepatitis B Virus in Endemic Areas Among Patients With Hepatitis C Treated With Direct-acting Antiviral Agents.
Journal: Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
Published: March 31, 2016
Showing 1-10 of 10
Last Updated: 09/26/2026